Conversion to Advagraf
PreclinicalSmall molecule
Conversion to Advagraf is one of 35 small molecule programs targeting Kidney Transplant. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
114 competitors in Kidney Transplant
#DrugCompanyPhaseTrials
1Ultomiris
AstraZenecaPhase 3
Kerendia
BayerPhase 2
Felzartamab
BiogenPhase 3
Biological/vaccine
Vertex PharmaceuticalsPhase 3
Zemplar
AbbViePreclinical
Cysteine Hydrochloride
NovartisPreclinical
Sensipar
AmgenPreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Radicava
ShionogiPreclinical
Jardiance
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Conversion to Advagraf. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of British Columbia